Praluent Cost in Maryland 2026: Prices, Coverage, and How to Pay Less

What Is Praluent and Why Does It Cost So Much?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors in the liver. By blocking PCSK9, alirocumab keeps more LDL receptors active on hepatocyte surfaces, increasing LDL clearance from the blood [1]. The FDA approved alirocumab in July 2015 for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on top of diet and maximally tolerated statin therapy [2].

The pricing reflects the cost of biologics manufacturing. Monoclonal antibodies require mammalian cell culture systems, extensive purification steps, and cold-chain logistics that small-molecule generics do not. No FDA-approved biosimilar for alirocumab had reached the U.S. market as of early 2026, so Regeneron and Sanofi face no generic competition.

In ODYSSEY OUTCOMES (N=18,924), alirocumab 75 mg or 150 mg subcutaneously every two weeks reduced major adverse cardiovascular events by 15% relative to placebo in patients who had an acute coronary syndrome within the prior 1-to-12 months (HR 0.85 to 95% CI 0.78-0.93, P<0.001) [3]. That trial enrolled patients on maximally tolerated statins, which is exactly the population Maryland prescribers encounter when deciding whether to add a PCSK9 inhibitor.

Praluent List Price in Maryland in 2026

The manufacturer list price (also called the wholesale acquisition cost, or WAC) for Praluent in Maryland is approximately $580 per month in 2026, covering two auto-injector pens at either the 75 mg or the 150 mg dose. That price is the same across all U.S. states because Regeneron and Sanofi publish a national WAC.

Cash-pay patients at Maryland retail pharmacies pay close to that WAC. GoodRx and similar discount platforms may trim the price modestly, but the savings are rarely dramatic for biologics. Expect to pay $500-$580 out of pocket per month without insurance or a manufacturer coupon.

The 75 mg dose is typically the starting dose for most patients. Clinicians measure LDL-C after four weeks and may uptitrate to 150 mg if the LDL-C goal has not been reached [2]. Patients who stay on 75 mg pay the same monthly price as those on 150 mg because the per-pen price is the same.

Maryland Medicaid Coverage for Praluent

Maryland Medicaid covers Praluent for qualifying diagnoses, but a prior authorization (PA) is required [4]. The two qualifying indications are:

1. Heterozygous familial hypercholesterolemia (HeFH) confirmed by either clinical criteria (Dutch Lipid Clinic Network score or Simon Broome criteria) or genetic testing.
2. Established ASCVD (prior MI, prior stroke, or symptomatic peripheral arterial disease) with inadequate LDL-C control despite maximally tolerated statin therapy.

For most Maryland Medicaid PA requests, the prescriber must document that the patient has been on a maximally tolerated statin for at least three months and that LDL-C remains above the goal. The specific LDL-C threshold Maryland Medicaid uses is typically 70 mg/dL for ASCVD patients and 100 mg/dL for HeFH patients, though plan-level coverage criteria are updated annually and prescribers should verify the current Maryland Medicaid Preferred Drug List (PDL) before submitting a PA.

Patients who are dually eligible for Medicare and Medicaid should note that the Regeneron/Sanofi savings card does not apply to their prescriptions. Medicare Part D covers Praluent under its specialty tier, and cost-sharing depends on the specific Part D plan's formulary placement.

Commercial Insurance and Prior Authorization in Maryland

Most commercial insurance plans in Maryland, including CareFirst BlueCross BlueShield, UnitedHealthcare, and Cigna, cover Praluent under specialty pharmacy benefits, but they impose step-therapy requirements. Step therapy typically demands documentation of:

• Three to six months on a high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) at maximally tolerated doses.
• A trial of ezetimibe 10 mg if LDL-C remains above goal after the statin trial.
• An LDL-C measurement above the plan's threshold after those trials.

If a patient has statin intolerance, the prescriber may submit a medical exception letter. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states that "in patients with very high-risk ASCVD, if LDL-C remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy, addition of a PCSK9 inhibitor is recommended" [5]. Citing that guideline language directly in the PA letter strengthens the case.

Some plans require specialty pharmacy dispensing rather than retail pharmacy dispensing. CVS Specialty and Accredo are common specialty pharmacy partners in Maryland. The prescriber's office submits the PA, and once approved, the specialty pharmacy ships the medication to the patient in a temperature-controlled package.

Approval timelines vary from 3 to 14 business days depending on the insurer. Maryland has a 72-hour urgent PA review requirement for situations where a delay would seriously jeopardize the patient's health, under Maryland Insurance Code § 15-10B.

The Regeneron/Sanofi Savings Card: How It Works in Maryland

The Praluent savings card (sometimes called the Praluent PAP or patient support program) is available through the Regeneron/Sanofi Praluent website and can reduce the monthly copay to $0 for eligible commercially insured patients. Here is what Maryland residents need to know:

• Eligibility: You must have commercial insurance that covers Praluent. Government insurance (Medicare, Medicaid, TRICARE) disqualifies you from using the card.
• Savings cap: As of 2026, the card covers up to $16,000 per calendar year in copay costs. Most commercially insured patients in Maryland stay well below that cap.
• Enrollment: You or your prescriber enrolls online or by phone. The card can be used at retail or specialty pharmacies that accept it.
• Renewal: The card requires annual re-enrollment. Missing the renewal deadline means a gap in coverage until the next enrollment cycle opens.

For patients who are uninsured, Regeneron and Sanofi offer the Praluent Patient Assistance Program (PAP), which may provide free medication to qualifying patients below a certain income threshold. Income documentation is required. A HealthRX care coordinator can walk Maryland patients through the enrollment steps.

Compounded Alirocumab in Maryland: Legality and Practicality

Compounded alirocumab is available through select 503A compounding pharmacies licensed in Maryland, and it is legal under current federal and state pharmacy law, with important caveats. Here is the legal framework that applies:

503A pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act. They compound for individual patients based on a valid prescription. They are not subject to FDA facility registration or cGMP requirements in the same way that 503B outsourcing facilities are, but they must comply with USP standards and their state board of pharmacy.

Maryland Board of Pharmacy licenses 503A compounding pharmacies and enforces USP <797> sterile compounding standards for injectable preparations. A compounded alirocumab subcutaneous injection qualifies as a sterile preparation and must be compounded under USP <797> conditions.

The key legal question concerns whether alirocumab is on the FDA's list of drugs that may not be compounded (the "do not compound" list under 503A) or whether it is commercially available in a form that makes compounding presumptively inappropriate. As of early 2026, alirocumab is not on the Section 503A(b)(1)(D) list. Compounding pharmacies may prepare it for individual patients with a valid prescription, provided the pharmacy does not compound it in quantities that suggest commercial manufacturing.

Practical note: Because alirocumab is a large-molecule biologic, not all 503A pharmacies have the analytical capability to verify batch potency and sterility. Patients should ask any compounding pharmacy for their certificate of analysis (COA) and sterility testing documentation for each batch. A pharmacy that cannot provide those documents should not be dispensing compounded injectable biologics.

The cost of compounded alirocumab from a Maryland-licensed 503A pharmacy can be substantially lower than the $580/month WAC, sometimes approaching $0/month for select programs, though pricing varies widely by pharmacy.

Prescribers should document medical necessity for the compounded formulation, which most commonly applies when a patient cannot afford the brand-name product and does not qualify for the savings card or PAP.

LDL-C Goals and Who Needs Alirocumab in Maryland

The ACC/AHA 2018 guideline defines "very high-risk" ASCVD as two or more major ASCVD events or one major event plus multiple high-risk conditions [5]. For those patients, the optional LDL-C threshold for adding a PCSK9 inhibitor is 70 mg/dL after maximally tolerated statin and ezetimibe. The guideline authors write: "The addition of a PCSK9 inhibitor to maximally tolerated statin therapy is reasonable for very-high-risk patients with ASCVD whose LDL-C level remains 70 mg/dL or higher."

For HeFH patients without established ASCVD, the threshold is an LDL-C above 100 mg/dL on maximally tolerated statin, per the FH guidelines from the European Atherosclerosis Society [6].

Maryland has a meaningful HeFH burden. Population genetics data suggest HeFH affects approximately 1 in 250 adults in Western populations, which translates to roughly 24,000-25,000 Marylanders with HeFH based on the state's adult population of approximately 6.1 million [7]. Many remain undiagnosed. Cascade screening of first-degree relatives of index HeFH cases is recommended by the National Lipid Association.

Alirocumab vs. Evolocumab in Maryland: Price Comparison

Evolocumab (Repatha, Amgen) is the other approved PCSK9 inhibitor in the U.S. market. Its WAC in 2026 is similarly around $560-$580/month. The two drugs have not been compared in a head-to-head randomized trial, but both produce LDL-C reductions of 50-65% from baseline on top of statin therapy [3, 8].

Maryland insurance plans that cover one PCSK9 inhibitor typically cover both, though some place one on a preferred tier. If a PA for Praluent is denied, it may be worth requesting Repatha on the same documentation, or appealing with additional clinical notes.

The savings card mechanics for Repatha (Amgen's PCSK9 Connect program) are similar to Praluent's. Both are commercially insured only and require annual renewal.

Telehealth Prescribing of Praluent in Maryland

Maryland permits telehealth prescribing of Praluent. Under Maryland law and the Maryland Board of Physicians' telehealth guidance, a prescriber may establish a valid patient-provider relationship via synchronous audio-video visit and then prescribe alirocumab if the clinical criteria are met.

Praluent is not a controlled substance, so there are no DEA telemedicine restrictions that apply. The prescriber still needs access to the patient's lipid panel (LDL-C, total cholesterol, HDL-C, triglycerides), a documented history of ASCVD or HeFH, and a record of prior statin therapy to support the prescription and any PA submission.

HealthRX conducts initial lipid consultations by video, reviews uploaded lab results, and submits PAs to Maryland insurance plans. For patients who prefer a local lipid specialist, the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease and the University of Maryland Medical Center Lipid Clinic both see high-risk lipid patients in person.

Maryland-Specific Patient Support Resources

Several resources exist specifically for Maryland patients who need help affording Praluent:

1. Maryland Medicaid HealthChoice: Covers Praluent with PA for qualifying HeFH and ASCVD patients. The Maryland Department of Health publishes the current PDL at health.maryland.gov.
2. Maryland Pharmaceutical Assistance Program (MPAP): Assists Maryland residents age 65 or older with Medicare Part D cost-sharing. PCSK9 inhibitors on the Part D formulary may qualify. The program is run through Maryland's Department of Aging.
3. RxHelp Maryland / NeedyMeds: NeedyMeds.org lists state-level assistance programs and manufacturer PAPs. Patients can search by drug name.
4. HealthRX prior authorization support: HealthRX care coordinators submit PA paperwork, handle insurer appeals, and enroll patients in the Regeneron/Sanofi savings card program at no extra charge for Maryland telehealth patients.

A 2023 analysis in JAMA Cardiology found that prior authorization denials for PCSK9 inhibitors were reversed on appeal in approximately 40% of cases when the appeal included guideline citations and patient-specific cardiovascular risk data [9]. Persistence through the appeals process, with clinical documentation, produces results.

Side Effects That Can Affect Treatment Adherence and Cost Planning

Alirocumab is generally well tolerated. The most common adverse effects in ODYSSEY OUTCOMES were injection-site reactions (occurring in 3.8% of alirocumab patients vs. 2.1% of placebo patients) and nasopharyngitis [3]. Neurocognitive events, a theoretical concern with very low LDL-C levels, were not significantly elevated in the trial population.

Patients who experience injection-site reactions sometimes discontinue therapy, which wastes the cost already incurred and resets the PA clock if they want to restart. Rotating injection sites (abdomen, thigh, upper arm) reduces local reactions. The auto-injector needle is 27-gauge and 1/2 inch, which most patients tolerate without difficulty.

Cold-chain handling is required: Praluent must be stored in a refrigerator at 36-46 degrees Fahrenheit. Patients traveling within Maryland or out of state should carry pens in an insulated bag with ice packs for trips longer than four hours. Pens left at room temperature (below 77 degrees Fahrenheit) can be stored for up to 30 days before use, per the prescribing information [2].

How HealthRX Handles Alirocumab Prescriptions for Maryland Patients

HealthRX operates as a telehealth prescribing platform. Maryland-licensed physicians on the HealthRX medical team can:

• Review your lipid panel and cardiovascular history during a video visit.
• Determine whether alirocumab is appropriate based on ACC/AHA 2018 criteria [5].
• Submit a prior authorization to your Maryland commercial or Medicaid plan.
• Enroll you in the Regeneron/Sanofi savings card if you have qualifying commercial insurance.
• Connect you with a Maryland-licensed 503A compounding pharmacy if the brand-name cost remains unmanageable.
• Follow up on LDL-C response at four and twelve weeks after initiation.

The standard monitoring protocol used by the HealthRX lipid team checks LDL-C, ALT, AST, and creatine kinase at baseline and at the four-week mark, consistent with National Lipid Association monitoring recommendations [10].